Protalix BioTherapeutics, Inc.
PLX
$1.98
$0.021.02%
AMEX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | 606.13% | -184.76% | -27.22% | 107.44% | 21.24% |
| Total Depreciation and Amortization | 16.76% | 15.87% | 13.07% | 12.85% | 7.45% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 1,292.73% | 124.75% | -69.42% | 168.08% | -85.41% |
| Change in Net Operating Assets | 237.93% | 267.57% | -326.28% | -220.59% | -122.76% |
| Cash from Operations | 535.45% | -49.14% | -190.91% | -44.96% | -220.77% |
| Capital Expenditure | -148.69% | 5.18% | -472.41% | -150.58% | 48.83% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 83,166.67% | 95.24% | -100.03% | 12.50% | 25.00% |
| Cash from Investing | 1,453.53% | 92.74% | -102.48% | -143.33% | 48.51% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -97.04% | -95.97% | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -97.04% | -95.97% | 100.00% | -- | -- |
| Foreign Exchange rate Adjustments | -862.50% | -157.41% | -500.00% | 120.00% | -14.29% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 8,815.56% | 113.51% | -205.94% | 58.98% | -108.45% |